Targeting a specific receptor to treat autoimmune diseases and blood cancers
Official title: Targeting the long isoform of the prolactin receptor to treat autoimmune diseases and B-cell malignancies
Funded at Beckman Research Institute/city of Hope · NIH-10889016 · Data updated 2026-11-12
This study is looking at how a specific receptor related to prolactin might play a role in the development of certain blood cancers, especially in people with autoimmune disorders like lupus, to help find new ways to treat these conditions early on.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project start | July 15, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $416,328 |
| NIH project number | 5R37CA276517-02 |
| Project ID | NIH-10889016 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation would include individuals with autoimmune disorders or high-risk B-cell malignancies.
✕Less likely to help
Patients with non-B-cell malignancies or those without autoimmune conditions may not benefit from this research.
What this research studies
This research investigates how the long isoform of the prolactin receptor may contribute to the development of high-risk B-cell malignancies, such as certain types of leukemia and lymphoma. By understanding the molecular mechanisms that lead to these cancers, particularly in patients with autoimmune disorders like systemic lupus erythematosus, the research aims to develop early interventions. The approach involves studying the effects of prolactin on B-cell proliferation and survival, which could lead to new treatment strategies. Patients may be involved in trials that explore these new therapeutic options.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for patients with autoimmune diseases and B-cell malignancies.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Beckman Research Institute/city of Hope
Duarte, United States Active
Researchers
- Principal investigator: Swaminathan, Srividya — Beckman Research Institute/city of Hope
- Study coordinator: Swaminathan, Srividya
Related research
Other NIH-funded projects on the same topics.
-
Unified and fair multimodal learning for autoimmune diseases
A patient-friendly AI approach will combine many kinds of health data to improve diagnosis and personalized care for autoimmune diseases, including lupus.
-
Fair combined medical-data models for autoimmune diseases
A new computer model will learn from medical records, tests, scans, genetics, and wearable data to help spot autoimmune diseases earlier in people with symptoms or at higher risk.
-
Non-immunosuppressive, targeted immune therapies for autoimmune diseases
Aims to develop targeted treatments that selectively remove disease-causing B cells in autoimmune conditions like pemphigus vulgaris without broadly weakening the immune system.
-
Home-based monitoring of environmental exposures and biology for autoimmune diseases
This project develops ways for people with autoimmune conditions to collect environmental and biological data at home so researchers can link exposures to health changes over time.
-
Targeting a specific prolactin receptor form to help people with autoimmune diseases and B-cell cancers
A scientist is testing a new approach that targets a particular prolactin receptor to potentially treat autoimmune diseases and certain B-cell cancers.
-
Understanding B cell Behavior in SLE and Other Autoimmune Diseases
Researchers are studying how B cells and their epigenetic marks behave in people with autoimmune diseases like SLE to find new ways to treat these conditions.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.